Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

Fayi Wu, Stephanie O. Peacock, Shuyun Rao, Sandra K. Lemmon, Kerry L. Burnstein

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.

Original languageEnglish (US)
Pages (from-to)5463-5474
Number of pages12
JournalJournal of Biological Chemistry
Volume288
Issue number8
DOIs
StatePublished - Feb 22 2013

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth'. Together they form a unique fingerprint.

  • Cite this